Pharmaceutical Executive October 13, 2025
Key Takeaways
- Psychiatric disorders affect over 20% of US adults, presenting complex challenges in diagnosis and treatment due to frequent comorbidities.
- Despite past challenges, recent advancements in brain biology and precision psychiatry offer new opportunities for innovative treatments.
- Biopharma companies are exploring novel drug targets, mechanisms of action, and biomarkers to enhance patient care and address unmet needs.
- Strategic asset prioritization and robust go-to-market strategies are crucial for biopharma firms to succeed in the evolving psychiatry landscape.
Co-authors: Prateek Kanade, Chaitali Sodankar, Vamsi Ratnala, Shashwat Sharma, Kajal Dubey
Psychiatry is at a major transformative phase as the biopharma industry strives to tackle the complexities of different disorders, which impact more than 20% of the US adult population. The...
Today's Sponsors
Today's Sponsor